WOODIE
- 13 Feb 2004 10:36
after yesterdays agm statement the share price has risen 50% how much upside is left or is this another false dawn?

http://www.alexa.com/data/details/traffic_details/thewellnessshop.co.uk
womans hour link below.
http://www.bbc.co.uk/radio4/womanshour/04/2008_08_mon.shtml
WOODIE
- 11 Oct 2007 10:44
- 807 of 1525
well done cynic not many admit on a b/b a change of stance,are you in for long term or trading?
cynic
- 11 Oct 2007 10:48
- 808 of 1525
am always happy to admit when i change my mind, just plain wrong, and sometimes when i get it spot on!
at heart i am a trader using CFDs exclusively and rarely hold for more than 3/6 months ...... with ULT, the price movement will almost certainly determine my actions - e.g. could trade some or even all of my holding very quickly if i feel it is all going too far too fast
robinhood
- 11 Oct 2007 11:17
- 809 of 1525
cynic from rns quote "We are delighted that the
Secretary of State has now committed the funds to ensure this is implemented and
we now expect the NHS to honour its LEGAL OBLIGATION and make Beating the Blues available to all patients who require it".unquote. Unless RNS is wrong unlikely that NHS wil renege
cynic
- 11 Oct 2007 11:23
- 810 of 1525
DOH! ..... why do you think my change of stance?
WOODIE
- 11 Oct 2007 11:27
- 811 of 1525
cynic thats why i asked long term or trading as the share has gone up from below 1p over the last month, profit taking will take place.
cynic
- 11 Oct 2007 11:34
- 812 of 1525
that is true, but without an rns to support the rise, there was no way i would have jumped on board or recommended same
just for info, absolutely massive volumes today .... already 30m against a daily average of only 4m ...... while many stale holders may well be getting out, there is clearly still plenty of appetite for sp is still comfortably ahead on the day
robinhood
- 11 Oct 2007 11:43
- 813 of 1525
Bot these buggers at .83- sold them at 2.50. Bot back in at 1.50 then cried a bit , but as BTB had been approved by NICE thot it wud be only a matter of time b4 implementation by NHS. Pleased I did and at least in the foreseeable future there will be no competion to BTB as we all know now it takes yonks b4 NICE and NHS are ready to resp. approve and do business. Happily watching the orders to come in now in the next few months
WOODIE
- 11 Oct 2007 12:03
- 814 of 1525
cynic fair enough.
gbrown100
- 11 Oct 2007 14:39
- 815 of 1525
I bought these at 2.4 and never sold, have been watching it all dwindle away, maybe my apathy will be rewarded... or probably not lol
micky468
- 11 Oct 2007 19:10
- 816 of 1525
"The most important quality for an investor is temperament, not intellect... You need a temperament that neither derives great pleasure from being with the crowd or against the crowd."................. (nice to have you on board CYNIC )
cynic
- 11 Oct 2007 19:37
- 817 of 1525
i admit to enjoying being quite provocative at times, and have certainly tended to march to my own tune in many aspects of my life .... it can be a bit uncomfortable at times, but sometimes brings home the bacon against the odds
JoJaguar
- 12 Oct 2007 11:18
- 818 of 1525
Yes, but do you actually have anyone to share the bacon with...........or did they scarper a long time ago...........
cynic
- 12 Oct 2007 19:14
- 819 of 1525
??????????? strange comment even by my standards ..... obviously my wallet makes me a much greater object of desire that you clearly thought ..... Bernie Ecclestone has that magic in spades
ptholden
- 12 Oct 2007 23:39
- 820 of 1525
'object of desire' ?? jeez, makes the mind boggle ;)
cynic
- 13 Oct 2007 09:02
- 821 of 1525
the likes of you and fliper consider me "an object of desire" only on the golf course where a juicy pigeon is perceived!
WOODIE
- 13 Oct 2007 10:11
- 822 of 1525
copy of mail i received a couple of days ago in response to the reuters interview.
xxxxxx
Here is a copy of a response to that question I sent yesterday:
Firstly, thank you for your kind wishes and yes we are obviously delighted at Alan Johnson's announcement yesterday, which of course we are using to ensure the Gov't fulfils its commitment on Beating the Blues - You will recall in March that Patricia Hewitt stood up at the MIND conference and pronounced the availability of BtB in the NHS from April 07, further supported on the NHS Choices website, advising patients to ask their GP's for it.
It is indeed unfortunate, that Reuters chose to use one word from a lengthy interview that could be misconstrued in its inference, but whilst I cannot pre-empt the announcement of our results you should not link "abysmal" take up by the NHS with what I have previously said on the subject of sales. Primary Care Trusts buying on the basis of the now agreed national framework are, of course, not Ultrasis' only customers.
It could well be seen however as fair comment from me that following the aforementioned statements by the Gov't and DH that the only "collective purchase" in the last 6 months was by the East Midlands. Yes it is encouraging that we can still achieve strong sales in the face of this level of uptake but you and I both know that all our efforts in recent year's deserve to come to fruition in this key market and we should continue to apply whatever pressure we can in making this happen - for the benefit of the thousands of patients that would benefit as well as the commercial rewards to shareholders for their investment in this business.
I trust you found this helpful.
Nigel
WOODIE
- 23 Oct 2007 07:35
- 823 of 1525
Ultrasis PLC
23 October 2007
Ultrasis plc
Final results for the year ended 31 July 2007
Highlights
Turnover ahead 27% (42% ahead in the second half) on the previous year at
1,577,000 (2006: 1,243,000)
High renewal rate and strong sales pipeline for 2008 with some forward
contracts already in place
Deferred income of 1,388,000, 1,272,000 of which is revenue recognisable
within the financial year ending 31 July 2008
Group remains debt free. Cash balance of 879,000 (2006: 872,000)
Company is self financing with projected income flows to cover both working
capital and development needs from internal resources
Implementation of Beating the Blues(R) across PCTs expected to benefit from
the additional 170m funding of psychological therapies recently announced
by the Secretary of State
New 'blue chip' customers and partners: Priory Group, ICAS, Turning Point.
For further information please contact:
Ultrasis plc:
Nigel Brabbins, Chief Executive +44 (0) 20 7566 3900
nbrabbins@ultrasis.com
gbrown100
- 23 Oct 2007 14:13
- 824 of 1525
Wave goodbye to any gains you made over the last few weeks lol
cynic
- 23 Oct 2007 14:16
- 825 of 1525
yup .... typical sp performance by ULT, except this time i made the mistake of buying them earlier!
WOODIE
- 24 Oct 2007 07:06
- 826 of 1525
from todays times
Ultrasis
Ultrasis is a technology company whose main product, an interactive computer program aimed at treating mental health patients, became available for prescription on the NHS in March.
Ultrasis published its annual figures yesterday, showing a 27 per cent rise in revenues to 1.58 million, indicating that its Beating the Blues treatment is a hit for those doctors aware of its availability as an affordable alternative to the usual range of antidepressant drugs.
Ultrasiss treatment has been endorsed by NICE, the government watchdog that monitors clinical efficacy and cost-effectiveness. The Health Secretary has committed 170 million of extra funding over three years so that all mental health patients can have access to nondrug therapies. NICE calculates that the NHS could save about 128 million a year from switching drug therapy patients to the Beating the Blues cognitive therapy course.
Uptake of the treatment has not been as quick as the company would like. Since March only 24 of the countrys 153 primary care trusts have made Beating the Blues available to GP practices. Doctors are, however, notoriously slow to change prescribing habits. Ultrasis is debt-free, meaning that investors can afford to wait for usage to increase in line with government expectations.
Ultrasis edged down yesterday to 0.95p but should be prescribed as a buy for investors.